FDA said to misuse "approvable" letters to delay decisions

06/7/2006 | Bloomberg Businessweek

Drugmakers complain the FDA is issuing "approvable" letters to gain more time to review submitted drugs, allowing the agency to avoid the six- to 10-month time limit for it to act. Some say the increase in the number of approvable letters is indicative of an overall slowdown at the agency.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD